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Cross-sectional analyses showed that the prevalence of basal core promoter (BCP) double mutations (nt
1762T, 1764A) of hepatitis B virus (HBV) gradually increases with age. We aimed to determine the inci-
dence rate of the mutations over 10 years. Study subjects were selected from the Long An cohort estab-
lished in 2004, including 59 with HBV with single mutations at nt 1762 or 1764 in the BCP and 342 with
wild type BCP sequences at baseline. Their serum samples for analysis were obtained at the 3rd and 10th
annual visits, respectively. The results showed that the annual incidence rate of BCP double mutations is
3.8% (95% conﬁdence interval [CI]: 1.4–6.2) and tends to decrease with age. The peak incidence is in the
30–34 years age-group. The incidence rate in HBeAg positive individuals (5.5%) is signiﬁcantly higher
than in those without HBeAg (3.4%) (P < 0.05). The incidence rate is signiﬁcantly higher in genotype C
(4.8%) than in genotype B (2.8%) or I (3.1%). The incidence rate of the mutations (6.8%) developing from
a single mutation at nt 1762 or 1764 is signiﬁcantly higher than that (3.8%) from the wild type sequence
(P < 0.005). The difference in incidence of single mutations between nt 1762 (0.7%) and 1764 (0.03%) is
signiﬁcant (P < 0.05). In conclusion, the incidence rate of BCP double mutations tends to decrease with
age after the age of 35 years. Viruses with a single mutation at nt 1762 or 1764 are more prone to develop
double mutations. Nt 1762 is the more common site of the ﬁrst mutation.
 2015 Published by Elsevier B.V.1. Introduction
HBV has a circular, partially double-stranded DNA genome of
about 3200 nt with four open reading frames (ORFs), namely the
core/precore, polymerase, surface and X ORFs (Tiollais et al.,
1985). Transcription of the four ORFs is controlled by the core,
large surface, major surface and X promoters, respectively. The
core promoter, located between nt 1575 and 1849, consists of
the basal core promoter (BCP) (nt 1743–1849) and the upper reg-
ulatory region (URR, nt 1613–1742), the latter containing both pos-
itive and negative regulatory elements that modulate promoter
activity. The core promoter plays a central role in HBV replication
and morphogenesis, directing the transcription of both species of3.5 kb mRNA: pregenomic RNA (pgRNA) and precore mRNA
(pre-C mRNA) (Kramvis and Kew, 1999; Quarleri, 2014).
The lack of proof-reading during reverse transcription of the
pregenomic RNA favours the development of sequence variants
during long-term HBV replication (Harrison, 2006). One of the
most critical changes is the appearance of the double mutations
at nt 1762 (A? T) and 1764 (G? A) in the BCP. These double
mutations, which result in a decrease in the levels of expression
of HBeAg and an increase in viral DNA replication (Buckwold
et al., 1996; Scaglioni et al., 1997), were ﬁrst described in the core
promoter of HBV from Japanese patients (Sugai et al., 1994; Sato
et al., 1995). Subsequently, we and others found that the core pro-
moter double mutations are associated with progressive liver dis-
eases, including hepatocellular carcinoma (HCC) (Nagasaka et al.,
1998; Fang et al., 1998, 2002; Kao et al., 2003). The association
between the double mutations and HCC has been conﬁrmed by
prospective studies (Fang et al., 2008a; Yuen et al., 2009; Chu
et al., 2012).
76 X.-Y. Wang et al. / Infection, Genetics and Evolution 34 (2015) 75–80Cross-sectional analyses showed that the prevalence of BCP
double mutations gradually increases with age (Nie et al., 2012;
Yan et al., 2012). However, data regarding the rate of naturally
occurring mutations remain lacking. Although there are a few
reports of the development of the double mutations during
HBeAg seroconversion, these focused only on the time around
the seroconversion of HBeAg (Nie et al., 2012; Chen et al., 2007),
which may result in a biased interpretation of the rate of double
mutations because BCP double mutations occur more frequency
during HBeAg seroconversion (Yuen et al., 2002; Yamaura et al.,
2003; Ni et al., 2004).
In this study, based on the Long An cohort (Fang et al., 2008a),
we determined the incidence rate of naturally occurring BCP dou-
ble mutations in HBsAg asymptomatic carriers over 10 years.
Meanwhile, we also determined the incidence rate of single muta-
tions (T1762 or A1764) and the incidence rate of double mutations
developing from a single mutation (T1762 or A1764).2. Materials and methods
2.1. Study subjects and sample design
In order to determine the value of screening carriers of hepatitis
B surface antigen (HBsAg) for virus with BCP double mutations as a
marker of an extremely high risk of developing HCC, a cohort of
2258 hepatitis B surface antigen positive subjects aged 30–55
was recruited in Guangxi, China early in 2004. This cohort included
1261 subjects with BCP double mutations and 997 with the wild
type BCP. We followed the study subjects for three years from
1st July, 2004 (Fang et al., 2008a). Each study subject completed
a one-page questionnaire at the ﬁrst visit and provided a serum
sample every six months for the assessment of virological param-
eters and AFP concentrations, and was monitored for HCC by ultra-
sonography (US). Then, we followed up for HCC cases but without
blood samples drawn every year. We followed up this cohort early
in 2014 and collected serum samples again. The study subjects for
this study were selected from subjects available for the 10th year
visit. The selection criterion is that they were infected with HBV
with wild type sequence of BCP at baseline.
In additional, when we established the Long An cohort in 2004,
we found some were infected with HBV with a single mutation at
nt 1762 or 1764 in BCP. Although they were excluded from the
Long An cohort, as controls, we followed up them for three years.
Serum samples collected from these subjects during the last visit
in the 3rd year were also included in this study.
Informed consent was obtained from each individual. The study
protocol conformed to the ethical guidelines of the 1975 declara-
tion of Helsinki and has been approved by the Guangxi
Institutional Review Board.
2.2. Baseline serological testing and HBV DNA ampliﬁcation and
nucleotide sequencing
The baseline sera testing for HBsAg, HBeAg/anti-HBe, alanine
aminotransferase (ALT) levels and HBV core promoter ampliﬁca-
tion and nucleotide sequencing have been reported previously
(Fang et al., 2008a).
2.3. Nested PCR for HBV DNA and nucleotide sequencing
DNA was extracted from 85 ll serum by pronase digestion fol-
lowed by phenol/chloroform extraction. The method to amplify
and sequence BCP regions is the same as previously report (Fang
et al., 2008a). To amplify the S region, the ﬁrst round polymerase
chain reaction (PCR) was carried out in a 50 ll reaction usingprimers MD14 (nt 418–433, 50- GCGCTGCAGCTATGCCTCATCTT
C-30) and HCO2 (nt 761–776, 50-GCGAAGCTTGCTGTACAGACTTG
G-30) with 5 min hot start followed by 35 cycles of 94 C for 45 s,
45 C for 45 s, and 72 C for 120 s. Second round PCR was carried
out on 5 ll of the ﬁrst round products in a 50 ll reaction using pri-
mers ME15 (nt 455–470, 50-GCGCTGCAGCAAGGTATGTTGCCCG-30)
and HDO3 (nt 734–748, 50-GCGAAGCTTCATCATCCATATAGC-30)
with 5 min hot start followed by 30 cycles of 94 C for 45 s, 55 C
for 45 s, and 72 C for 120 s. Products from the second round were
conﬁrmed by agarose gel electrophoresis. HBV DNA positive prod-
ucts were sent to The Sangon Biotech (Shanghai, China) for
sequencing using a BigDye Terminator V3.1 Cycle Sequencing kit
(Applied Biosystems, Foster City, USA) with sequencing primer
ME15.
2.4. Measurement of viral loads
Viral load measurements were carried out as described by
Garson et al. (Garson et al., 2005). Brieﬂy, HBV DNA was extracted
from serum samples using a Qiagen BioRobot 9604 and QIAamp96
Virus Kit reagents (Qiagen, Hilden, Germany). Viral DNA was
ampliﬁed and quantiﬁed in an ABI Prism 7000 sequence detection
system (Applied Biosystems, Foster City, CA, USA) using HBV pri-
mers and a dual labeled TaqMan probe as described.
2.5. HBV genotyping
HBV genotypes were determined using the sequences above
and the NCBI Genotyping Tool (http://www.ncbi.nlm.nih.gov/pro-
jects/genotyping/formpage.cgi) and the STAR program (http://
www.vgb.ucl.ac.uk/starn.shtml) (Myers et al., 2006).
2.6. Statistical analysis
The 95% conﬁdence limits (CI) for the incidence rate of HBV
mutations were estimated. Viral loads are presented as median
(range). Variables were compared between groups using the
chi-square test. Logistic regression analysis was carried out to
identify factors that affect the development of BCP double muta-
tions. All P-values were two-tailed and P < 0.05 was considered
to be signiﬁcant. All statistical analyses were performed using
the SPSS software (ver.16.0; Chicago, IL, USA).
3. Results
3.1. Baseline characteristics
The study subjects consisted of 342 HBsAg positive asymp-
tomatic individuals, including 183 males and 159 females. The
youngest and oldest were 40 and 65 years old. The average age
(mean ± SD) was 50.1 ± 6.3 years. The average ages of males and
females were 48.9 ± 6.0 and 51.5 ± 6.3 years, respectively. One
hundred and ﬁve (30.7%) study subjects were HBeAg-positive
and 237 (69.3%) were HBeAg-negative. Three genotypes were iden-
tiﬁed, B, C and I, with a prevalence of 41.2%, 47.4% and 11.4%
respectively. None of them had received antiviral therapy.
3.2. The incidence rate of BCP double mutations
One hundred and twenty-nine of 342 individuals infected with
HBV with wild type BCP sequences at baseline developed double
mutations after 10 years, giving the overall annual incidence of
3.8% (95% conﬁdence interval [CI]: 1.4–6.2). The incidence rates
of the double mutations in males and females are 3.9% (95% CI:
1.1–6.7) and 3.5% (95% CI: 0.7–6.4), respectively (Table 1); this
Table 1
The incidence rate of BCP double mutations, by gender.
Gender Number Number of double
mutations
Incidence
rate (%)
Annual incidence
rate (%) (95% CI)
Male 183 73 38.9 3.9 (1.1–6.7)
Female 159 56 35.2 3.5 (2.9–6.4)
Total 342 129 35.7 3.6 (1.6–5.6)
The differences in the incidence rate of BCP double mutations between males and
females is X2 = 0.790, P > 0.05.
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of BCP double mutations trends to decrease with age and the high-
est was seen in the youngest age group (30–34 years old at base-
line) (Fig. 1).3.3. Single mutation at nt 1762 or 1764 are intermediates in the
development of the double mutations
At baseline, there were ﬁfty-nine individuals with single BCP
mutation, 22 with nt 1762 A? T and 37 with nt 1764 G? A.
After three years of follow-up, those with a single mutation at nt
1762 at baseline had a higher incidence of double mutations thanFig. 1. The incidence rate of BCP double mutations, by age.
Table 2
The incidence rate of BCP double mutations developing from single mutations over
three years.
Type of single
mutation at
baseline
Number Progressed to double
mutations (nt 1762T,
nt 1764A) at third year
Annual incidence
rate (%)
nt 1762T 22 6 9.1 (2.9 to 21.1)
nt 1764A 37 6 5.4 (1.9 to 12.7)
Total 59 12 6.8 (0.4 to 13.2)
The differences in the incidence rate of BCP double mutations between nt 1762T
and nt 1764A is X2 = 0.4704, P > 0.05.
Table 3
The incidence rate of single mutations developing from wild type BCP sequences over ten
Gender No. nt 1762A? T
mutation
Annual incidence rate
(%) (95% CI)
nt 1764G? A
mutation
A
(%
Male 183 14 0.8 (0.5 to 2.1) 0 0
Female 159 10 0.6 (0.6 to 1.8) 1 0
Total 342 24 0.7 (0.2 to 1.6) 1 0those with nt 1764 G? A (9.1% vs. 5.4%), although the difference is
not signiﬁcant (X2 = 0.4704, P > 0.05). The overall annual incidence
rate of BCP double mutations of the 59 subjects is 6.8% (95% CI:
0.4–13.2), which is signiﬁcantly higher than the annual incidence
of 3.8% of the double mutations developing from the wild type
BCP sequence (X2 = 21.566, P < 0.05), suggesting that a single muta-
tion at 1762 or 1764 is a step to the double mutation (Table 2).
Twenty-four of the 342 individuals developed an A? T point
mutation at nt 1762 during the ten years, giving the annual inci-
dence of 0.7% (95% CI: 0.2 to 1.6). However, only one of the 342
developed a G? A point mutation at nt 1764, giving the annual
incidence of 0.03% (95% CI: 0.2 to 0.2). The difference in incidence
of single mutations between nt 1762 and 1764 is signiﬁcant
(X2 = 21.96, P < 0.05), suggesting that nt 1762 is the more common
site of the ﬁrst mutation (Table 3).
The data above show that single mutations at nt 1762 or 1764
developed from wild type of BCP and BCP double mutations devel-
oped later. However, these events occurred in different individuals.
In order to determine whether these events may occur in the same
individuals, twenty samples from subjects who were found to have
developed BCP double mutations by the 10th years were randomly
selected from the samples drawn at the 3rd year to determine the
sequence of the BCP. The results showed that two of them already
had developed BCP double mutations. Five of them had single
mutations, including three with 1762T and two with 1764A. The
remainder had wild type BCP sequences of at the 3rd year. These
data suggested that the single mutation of nt 1762 or 1764 are
intermediates in the development of the double mutations
(Table 4).
3.4. The incidence rate of double mutations and viral loads
The distribution of viral loads was skewed (median
3.09  104 IU/mL, range 0–2.64  109 IU/mL). The median viral
load at baseline is signiﬁcantly higher in those who developed
BCP double mutations after ten years than those who did not
develop the mutations (median 189,000 versus 21,234 IU/mL,
P = 0.02). The incidence rate of BCP double mutations is signiﬁ-
cantly higher in those with viral loadsP105 IU/mL than those with
viral loads <105 IU/mL (X2 = 8.141, P < 0.05). These data suggest
that the development of BCP double mutations is associated with
viral loads at baseline and viral loads P105 IU/mL in serum may
be a threshold to predict the likely development of BCP double
mutations.
3.5. The incidence rate of double mutations and HBeAg
The incidence rate of BCP double mutations in HBeAg positive
individuals (55.2%, 95% CI: 45.3–65.1) is signiﬁcantly higher in
those who are HBeAg negative (34.4%, 95% CI: 28.1–40.7)
(X2 = 12.02, P < 0.05). The rate of HBeAg seroconversion of
ﬁfty-three individuals who developed BCP double mutations after
ten years is 75.5% (40/53). Clearly, about one quarter of individuals
who developed BCP double mutations remained HBeAg positive,
consistent with the fact that the double mutations decrease but
not stop expression of HBeAg (Buckwold et al., 1996; Scaglioni
et al., 1997).years.
nnual incidence rate
) (95% CI)
nt 1762A? T
or1764G? A mutation
Annual incidence rate
(%) (95% CI)
14 0.8 (0.5 to 2.1)
.06 (0.3 to 0.4) 11 0.7 (0.6–2.0)
.03 (-0.2 to 0.2) 25 0.7 (0.2 to 1.6)
Table 4
Characteristics of individuals developing BCP double mutations from the wild type sequence via a single mutation.
Samples Gender. Ages Genotypes Viral loads (IU/ml) HBeAg ALT⁄ IU/ml) BCP sequence at
Baseline# 3rd year# 10th year#
CZ238 F 40 C 2.51E + 08 +  W 1762T M
DB253 M 44 B 5.17E + 07 + 285 W 1762T M
DJ017 F 40 C 2.80E + 06 +  W 1762T M
DJ053 F 37 B 78.2   W W M
DW454 F 36 C 1.16E + 08 +  W W M
DW456 M 34 B 22,698   W W M
GA024 M 31 I 3.04E+08 +  W W M
GM174 M 42 B 8.32E+07 +  W W M
GY43 F 52 B 8.80E+07 +  W W M
JD171 M 35 C 1.10E+07 + 59 W W M
ND128 F 35 C 8.16E+08 +  W W M
NX109 M 35 I 6.20E+08 +  W M M
TJ163 M 36 C 3.66E+08 +  W M M
TM083 M 35 C 5.90E+08 +  W W M
TS092 F 40 B 1.92E+08 +  W 1764A M
TX72 F 35 C 9.40E+07  66 W W M
WX288 M 42 C 5.00E+08 +  W W M
XW64 F 35 C 6.31E+08 +  W W M
YL340 F 35 B 3.51E+08 +  W 1764A M
YY416 F 42 C 3.72E+06 +  W W M
.: M, Male; F, Female. ⁄: ALT: alanine aminotransferase, ‘‘’’, normal ALT, the cut-off is 40 IU/ml. #: W, wild type, M: BCP double mutations.
Table 5
The incidence rate of BCP double mutations by genotype.
Gender Number Number of double mutations Incidence rate (%) Annual incidence rate (%) (95% CI)
Genotype B 141 39(9) 27.7 2.8 (0.1–5.5)
Genotype C 162 78(12) 48.2 4.8 (1.5–8.1)
Genotype I 39 12(4) 30.8 3.1 (2.3 to 8.5)
Total 342 129(25) 37.7 3.8 (1.8–5.8)
The differences in the incidence of BCP double mutations between genotypes C and B, and C and I, are X2 = 13.351 and X2 = 3.840, respectively, both P < 0.05. The difference in
the incidence of BCP double mutations between genotypes B and I is not signiﬁcant (X2 = 0.145, P > 0.05).
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The annual incidence rates of BCP double mutations in geno-
types B, C and I are 2.8% (95% CI: 0.1–5.5), 4.8% (95% CI: 1.5–8.1)
and 3.1% (95% CI: 2.3 to 8.5), respectively. The differences in
the incidence of BCP double mutations between genotypes C and
B, and C and I, are X2 = 13.351 and X2 = 3.840, respectively, both
P < 0.05. But the difference in the incidence of BCP double muta-
tions between genotypes B and I are not signiﬁcant (X2 = 0.145,
P > 0.05). These data suggest that genotype C is associated with
the development of BCP double mutations (Table 5).3.7. Analysis for factors associated with the development of BCP double
mutations
Multivariable logistic regression analysis was carried out to
identify factors that affect the development of BCP double muta-
tions. The independent variables included sex, age, viral loads,
HBeAg, genotypes and ALT. On univariate analysis, viral loads,
genotypes and HBeAg status were independently associated with
the development of BCP double mutations but sex, age and ALT
were not. On multivariate analysis, genotype C was associated with
the development of BCP double mutations (OR = 2.253, P = 0.001)
(Table 6).4. Discussion
To our knowledge, this is the ﬁrst study to report the annual
incidence rate of naturally occurring, cancer related mutations inthe basal core promoter of hepatitis B virus. The major ﬁndings
of the study are that the annual incidence rate of BCP double muta-
tions is 3.8%. The incidence rate of BCP double mutations trends to
decrease with age after the age of 35 years and the highest was
seen in the youngest age group (30–34 years group) in the cohort.
The single mutations nt 1762 and 1764 are intermediates in the
development of the double mutations and nt 1762 is the more
common site of the ﬁrst mutation. Genotype C and HBeAg status
are associated with the development of BCP double mutations.
The strength of this study is that the data are derived from a
long-term prospective study, which makes them very relevant. A
weakness of this study is that the study subjects did not include
individuals younger than 30 years old, so we could not obtain the
incidence rate of BCP double mutations for these age groups.
Another weakness is that we did not sequence the PreS1/S2 region
that has been reported to be associated with the development of
HCC (Fang et al., 2008b), so we could not obtain the incidence rate
of this region.
It has been reported from cross-sectional studies that the preva-
lence of BCP double mutations increased with age (Fang et al.,
2008a; Nie et al., 2012; Yin et al., 2010). The prevalence is about
6–8% in those aged below 15 years old (Yin et al., 2010; Kang
et al., 2011) and about 25–69% in adults (Yuen et al., 2002; Yin
et al., 2010). However, the annual incidence rate of BCP double
mutations remains unclear. There are a few studies regarding the
development of BCP double mutations (Chen et al., 2007; Nie
et al., 2012), unfortunately, most studies have focused on the time
around seroconversion of HBeAg (Chen et al., 2007; Nie et al.,
2012). BCP double mutations occur more frequently during
HBeAg seroconversion (Yuen et al., 2002; Yamaura et al., 2003;
Table 6
Logistic regression analysis for factors associated with the development of BCP double mutations.
Analysis models Variables p Value Hazard ratio 95% CI for hazard ratio
Lower Upper
Univariate analysis Sex
Female⁄
Male 0.374 1.221 0.786 1.895
Ages
30–34⁄
35–40 0.511 0.809 0.430 1.523
40–45 0.423 0.758 0.385 1.492
45–50 0.024 0.355 0.144 0.872
50- 0.315 0.670 0.307 1.462
Genotypes
Genotype B⁄
Genotype C 0.00 2.429 1.502 3.928
Genotype I 0.703 1.162 0.536 2.520
Viral loads
No⁄
P105 IU/ml 0.006 1.870 1.199 2.917
HBeAg
Negative⁄
Positive 0.001 2.159 1.350 3.454
ALTN
<40 IU/ml
P40 0.773 1.087 0.616 1.918
Multivariate analysis Genotypes
Genotype B⁄
Genotype C 0.001 2.253 1.381 3.676
Genotype I 0.848 1.080 0.492 2.368
HBeAg (+) 0.003 2.070 1.277 3.354
*The variable used for comparison; ALT, NAlanine aminotransferase.
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mutation rate of the double mutations. In this study, we included
both HBeAg-positive and -negative study subjects, with a
long-term follow up. We found that BCP double mutations
occurred in both HBeAg-positive and -negative study subjects,
although the rate in individuals with HBeAg is signiﬁcantly higher
than in those who are HBeAg negative. Furthermore, our study
subjects are all HBsAg asymptomatic carriers and have not
received antiviral therapy. Therefore, our results more likely reﬂect
the natural rate of development of BCP double mutations.
The causal relationship of HCC and the double mutations has
been conﬁrmed by prospective studies (Fang et al., 2008a; Yuen
et al., 2009; Chu et al., 2012). The incidence of HCC increases with
age (Yang and Roberts, 2010; Nordenstedt et al., 2010). In Guangxi,
China, the peak age of diagnosis with HCC is 45–49 years (Zhang
et al., 1997). We found that the incidence rate of BCP double muta-
tions is highest in age group of 30–34, which conﬁrmed our previ-
ous ﬁnding from a cross-sectional study (Fang et al., 2008a) that
the prevalence of BCP double mutations is highest in the group
aged 40–44. It is reasonable to speculate that BCP double muta-
tions developed about 10 years before the development of HCC.
Therefore, our ﬁndings are important to understand the mecha-
nisms of oncogenesis of BCP double mutations.
BCP double mutations constitute a typical pattern of mutations
in the core promoter and are seen most frequently, while single
mutations at nt 1762 and 1764 are rarely detected in HBV patients
(Sugai et al., 1994; Buckwold et al., 1997). It is unclear whether the
development of BCP double mutations is via a single mutation. In
this study, we found that single mutations at nt 1762 or 1764
developed from the wild type BCP and then progressed to BCP dou-
ble mutations, suggesting that the single mutations at nt 1762 or
1764 are intermediates in the development of the double muta-
tions. Furthermore, we found that nt 1762 is the favoured site for
the initial mutation. HBeAg is not required for viral replication
(Tong et al., 1991). However, the loss of HBeAg may be a sign ofimmune escape (Carman et al., 1989). The nt 1762T mutation
can suppress precore RNA transcription, which decreases the pro-
duction of HBeAg and increases the efﬁciency of progeny virus syn-
thesis. In contrast, the nt 1764A mutant does not suppress precore
RNA transcription but reduces slightly the efﬁciency of virus pro-
geny synthesis (Buckwold et al., 1997). Therefore, it is possible that
nt 1762 develops mutation ﬁrst under immune pressure.
Data from cross-sectional studies showed that BCP double
mutations are associated with genotype. Genotypes C and D have
a higher frequency of BCP double mutations than genotypes A
and B (Kramvis and Kew, 1999; Quarleri, 2014). These ﬁnding were
conﬁrmed by our prospective cohort study. We found that the
annual incidence rate of BCP double mutations in genotype C is sig-
niﬁcantly higher than that of genotype C or I.
It has been reported that the double mutations decrease but do
not stop expression of HBeAg in cell culture (Buckwold et al., 1996;
Scaglioni et al., 1997). Cross-sectional studies also showed that not
all of individuals with BCP double mutations were negative for
HBeAg but the titer of HBeAg is lower (Qin et al., 2009; Yim
et al., 2015). We found that about one quarter of individuals
remain positive for HBeAg despite having double mutations in
the BCP.
In conclusion, the incidence rate of BCP double mutations tends
to decrease with age after the age of 35 years. Viruses with a single
mutation at nt 1762 or 1764 are more prone to develop double
mutations. Nt 1762 is the more common site of the ﬁrst mutation.
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